Article
Hematology
Guillermo Montalban-Bravo, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Farhad Ravandi, Kelly Chien, Naveen Pemmaraju, Danielle Hammond, Xiao Qin Dong, Xuelin Huang, Heather Schneider, Rosmy John, Rashmi Kanagal-Shamana, Sanam Loghavi, Hagop Kantarjian, Guillermo Garcia-Manero
Summary: Lower doses of CPX-351 show promising safety and activity in HR-MDS or CMML patients who have failed HMAs.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Thibault Comont, Mathieu Meunier, Amina Cherait, Clemence Santana, Thomas Cluzeau, Bohrane Slama, Kamel Laribi, Jean-Thomas Giraud, Sophie Dimicoli, Ana Berceanu, Lenaig Le Clech, Pascale Cony-Makhoul, Berangere Gruson, Jose Torregrosa, Laurence Sanhes, Vincent Jachiet, Marie-Agnes Azerad, Ahmad Al Jijakli, Emmanuel Gyan, Clement Gaudin, Jonathan Broner, Claire Guerveno, Thierry Guillaume, Pr Lionel Ades, Odile Beyne-Rauzy, Pierre Fenaux
Summary: This study demonstrates the effectiveness and tolerability of eltrombopag in patients with MDS and CMML, showing significant platelet responses with a relatively long duration. Despite some patients experiencing thrombotic events, the majority responded well to the medication with good treatment tolerance.
BRITISH JOURNAL OF HAEMATOLOGY
(2021)
Article
Rheumatology
M. Pean de Ponfilly-Sotier, V Jachiet, Y. Benhamou, C. Lahuna, B. De Renzis, D. Kottler, L. Voillat, S. Dimicoli-Salazar, A. Banos, M-P Chauveheid, J-F Alexandra, E. Grignano, F. Lifermann, M. Laborde, J. Broner, M. Michel, O. Lambotte, K. Laribi, M-D Venon, B. Dussol, N. Martis, S. Thepot, S. Park, D. Couret, M. Roux-Sauvat, L. Terriou, E. Hachulla, C. Bally, J. Galland, J-S Allain, A. Parcelier, P. Peterlin, J. Cohen-Bittan, A. Regent, F. Ackermann, J. Le Guen, C. Algrin, P. Charles, E. Daguindau, X. Puechal, B. Dunogue, C. Blanchard-Delaunay, O. Beyne-Rauzy, V Grobost, J. Schmidt, T. Le Gallou, G. Dubos-Lascu, A. Sonet, G. Denis, F. Roy-Peaud, P. Fenaux, L. Ades, O. Fain, A. Mekinian
Summary: This study found that venous thromboembolism (VTE) is common in patients with MDS/CMML-associated SIADs, and the impact of VTE on overall survival and progression to acute myeloid leukaemia is not significant. MDS/MPN is more common in patients with VTE.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2022)
Review
Oncology
Jan Philipp Bewersdorf, Amer M. Zeidan
Summary: MDS and CMML are two distinct blood cancers with variable symptoms and risks. Management decisions should be individualized and based on validated risk stratification tools. Supportive care is the mainstay for lower-risk patients, while bone marrow transplant is the only curative option for higher-risk patients.
Article
Hematology
Guillermo Montalban-Bravo, Rashmi Kanagal-Shamanna, Ziyi Li, Danielle Hammond, Kelly Chien, Juan Jose Rodriguez-Sevilla, Koji Sasaki, Elias Jabbour, Courtney DiNardo, Koichi Takahashi, Nicholas Short, Ghayas C. Issa, Naveen Pemmaraju, Tapan Kadia, Farhad Ravandi, Naval Daver, Gautam Borthakur, Sanam Loghavi, Sherry Pierce, Carlos Bueso-Ramos, Hagop Kantarjian, Guillermo Garcia-Manero
Summary: Chronic myelomonocytic leukaemia (CMML) is a blood disorder that has a high risk of transforming into acute myeloid leukaemia (AML). A study on a cohort of 189 CMML patients with AML transformation revealed distinct trajectories of transformation characterized by genomic profiles and clonal evolution: monocytic, immature myeloid, or erythroid. Monocytic AML was defined by specific mutations and was more likely to evolve from a specific type of CMML, while immature myeloid AML exhibited different mutations and had a higher frequency of a specific mutation. The study also observed potential benefits of a certain combination therapy for immature myeloid AML. These findings contribute to the understanding of CMML progression and provide a basis for the development of phenotype-specific therapeutics.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Jeffrey E. Lancet, Geoffrey L. Uy, Laura F. Newell, Tara L. Lin, Ellen K. Ritchie, Robert K. Stuart, Stephen A. Strickland, Donna Hogge, Scott R. Solomon, Dale L. Bixby, Jonathan E. Kolitz, Gary J. Schiller, Matthew J. Wieduwilt, Daniel H. Ryan, Stefan Faderl, Jorge E. Cortes
Summary: In this study, CPX-351 showed improved overall survival compared to 7+3 in newly diagnosed high-risk or secondary acute myeloid leukaemia patients aged 60-75 years. The 5-year follow-up results confirmed the benefits of CPX-351 in achieving long-term remission and improved overall survival in this patient population.
LANCET HAEMATOLOGY
(2021)
Review
Oncology
Shaykhah Alotaibi, Dietger Niederwieser, Syed Osman Ahmed, Jaime Sanz, Mohamad Mohty, Mahmoud Aljurf
Summary: AML treatment has evolved with the introduction of CPX-351 as a novel therapeutic approach, showing promise in improving the treatment outcomes for AML patients.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2022)
Letter
Oncology
Pauline Durand, Valerie Pottier, Charles Mesguich, Frederic Debordeaux, Estibaliz Lazaro, Jean-Francois Viallard, Etienne Riviere
Summary: This study analyzed the utility of indium-111 platelet scintigraphy (IPS) to better understand the mechanisms and guide treatment of thrombocytopenia in patients with myelodysplastic syndromes (MDS). The results showed that IPS can be a useful tool to identify and treat the increased bleeding risk caused by thrombocytopenia in MDS patients.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
(2023)
Letter
Dermatology
Roberto Maglie, Stefano Senatore, Gioia Di Stefano, Marta Barzacchi, Vincenza Maio, Francesca Montefusco, Maria Efenesia Baffa, Beatrice Bianchi, Marco Santucci, Emiliano Antiga
Summary: We describe an unusual case of myelodysplasia cutis in a patient with chronic myelomonocytic leukaemia.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2022)
Article
Immunology
Gregoire Martin de Fremont, Pierre Hirsch, Santiago Gimenez de Mestral, Philippe Moguelet, Yoan Ditchi, Jean-Francois Emile, Patricia Senet, Sophie Georgin-Lavialle, Thomas Hanslik, Francois Maurier, Amir Adedjouma, Noemie Abisror, Thibault Mahevas, Florent Malard, Lionel Ades, Pierre Fenaux, Olivier Fain, Francois Chasset, Arsene Mekinian
Summary: In most cases of MDS/CMML, skin lesions are characterized by a clonal myeloid infiltrate, and there is generally a similar mutational profile between blood/bone marrow and skin.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Oncology
Swapna Thota, Aram Oganesian, Mohammad Azab, Elizabeth A. Griffiths
Summary: Myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) are clonal hematopoietic stem cell disorders, commonly treated with azacitidine or decitabine, but a novel oral combination of DEC-cedazuridine (C-DEC) has shown promise as a more convenient treatment option.
Article
Oncology
Vincent Jachiet, Jerome Hadjadj, Lin-Pierre Zhao, Francois Chasset, Olivier Fain, Pierre Fenaux, Arsene Mekinian
Summary: Systemic inflammatory or autoimmune diseases are common in patients with myelodysplastic syndromes or chronic myelomonocytic leukemia. Recent advancements in molecular biology have provided insights into the pathophysiological mechanisms linking inflammatory manifestations and myeloid hemopathies. Treatment of these diseases remains challenging, but prospective data supports the use of demethylating agents as a therapeutic strategy.
BULLETIN DU CANCER
(2023)
Article
Medicine, General & Internal
Tanya Siddiqi, David G. Maloney, Saad S. Kenderian, Danielle M. Brander, Kathleen Dorritie, Jacob Soumerai, Peter A. Riedell, Nirav N. Shah, Rajneesh Nath, Bita Fakhri, Deborah M. Stephens, Shuo Ma, Tatyana Feldman, Scott R. Solomon, Stephen J. Schuster, Serena K. Perna, Sherilyn A. Tuazon, San -San Ou, Eniko Papp, Leanne Peiser, Yizhe Chen, William G. Wierda
Summary: In this study, lisocabtagene maraleucel (liso-cel) was evaluated for its efficacy and safety in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma. The results showed that liso-cel induced complete response or remission in patients, including those who had previously failed treatment with a BTK inhibitor and venetoclax. The safety profile was manageable.
Article
Oncology
John Paul Yun, Philip Q. Ding, Aastha Dolley, Winson Y. Cheung
Summary: DEC-C has been proven to be an effective oral treatment option for myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) in Canada. Real-world data from a compassionate use program showed that DEC-C may serve as a promising alternative to address the unmet needs of patients with MDS and CMML.
Letter
Dermatology
Lanyu Sun, Claudia Brazao, Dora Mancha, Luis Soares-de-Almeida, Cristina Tapadinhas, Paulo Filipe
Summary: We present a case of a 69-year-old woman with multiple adult xanthogranuloma preceding the diagnosis of chronic myelomonocytic leukaemia. There are limited reports on multiple adult xanthogranuloma in the literature, and this is the first report linking it to chronic myelomonocytic leukaemia.
CLINICAL AND EXPERIMENTAL DERMATOLOGY
(2023)